According to the National Alliance on Mental Illness (NAMI), approximately one in five adults in the U.S., which translates into a population base of around 43.8 million, experience mental illness in a given year. Among these, nearly 6.9% of them had a major depressive episode while 2.6 suffered from biopolar disorder. These escalating numbers are also being observed in various emerging economies too wherein rapid urbanization is underway, radically changing the lifestyle of the citizens. Consequently, a recent business intelligence study by Transparency Market Research (TMR) has notified that the demand in the global mental health therapeutics market will expand at a notable CAGR during the forecast period of 2017 to 2025.
The report is a comprehensive study of all market dynamics that will determine the demand for mental health specific therapeutics, analyzing each and every driver, trend, and restraint. The report also segments the market into smaller aspects and gauges the potential of demand that can be expected from various countries and regions. Beginning with an executive summary, the report finishes with a featured section on the competitive landscape in the global mental health therapeutics market. Overall, it is an all-inclusive study that has been prepared by a group of professional research analysts and aspires to serve as a credible business tool for its audiences.
Based on disease, the mental health therapeutics market can be segmented into anxiety disorders, mood disorders, substance abuse disorders, insomnia, binge eating disorder, and personality disorders.
Forest Laboratories, Pfizer, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca, Wyeth, Biogen, Inc., and Teva Pharmaceutical Industries Ltd. are some of the notable companies currently ahead of the curve in the global mental health therapeutics market. These companies are resiliently indulged in the research and development of new drugs that can gain FDA approvals.
Get Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=32171